Veterinary Medicines

Suiseng Suspension for injection for pigs

Not authorised
  • Escherichia coli, fimbrial adhesin F4ac
  • Escherichia coli, fimbrial adhesin F5
  • Clostridium perfringens, type C, beta toxoid
  • Clostridium novyi, type B, alpha toxoid
  • Escherichia coli, fimbrial adhesin F4ab
  • Escherichia coli, fimbrial adhesin F6
  • Escherichia coli, LT toxoid
Download as PDF

Product identification

Medicine name:
Suiseng Suspension for injection for pigs
Suiseng Vet injektioneste, suspensio
Active substance:
  • Escherichia coli, fimbrial adhesin F4ac
  • Escherichia coli, fimbrial adhesin F5
  • Clostridium perfringens, type C, beta toxoid
  • Clostridium novyi, type B, alpha toxoid
  • Escherichia coli, fimbrial adhesin F4ab
  • Escherichia coli, fimbrial adhesin F6
  • Escherichia coli, LT toxoid
Target species:
  • Pig
Route of administration:
  • Intramuscular use

Product details

Active substance and strength:
  • Escherichia coli, fimbrial adhesin F4ac
    78.00
    percent
    /
    1.00
    Dose
  • Escherichia coli, fimbrial adhesin F5
    79.00
    percent
    /
    1.00
    Dose
  • Clostridium perfringens, type C, beta toxoid
    35.00
    percent
    /
    1.00
    Dose
  • Clostridium novyi, type B, alpha toxoid
    50.00
    percent
    /
    1.00
    Dose
  • Escherichia coli, fimbrial adhesin F4ab
    65.00
    percent
    /
    1.00
    Dose
  • Escherichia coli, fimbrial adhesin F6
    80.00
    percent
    /
    1.00
    Dose
  • Escherichia coli, LT toxoid
    55.00
    percent
    /
    1.00
    Dose
Pharmaceutical form:
  • Suspension for injection
Withdrawal period by route of administration:
  • Intramuscular use
    • Pig
      • Meat and offal
        0
        day
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI09AB08
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Finland
Package description:
  • Cardboard box with 1 PET vial of 125 doses (250 ml). 250 ml PET plastic vials, closed with type I rubber stoppers and aluminium caps.
  • Cardboard box with1 PET vial of 50 doses (100 ml). 100 ml PET plastic vials, closed with type I rubber stoppers and aluminium caps.
  • Cardboard box with 1 glass vial of 25 doses (50 ml). 50 ml Type-I colourless glass vials, closed with type I rubber stoppers and aluminium caps.
  • Cardboard box with 1 glass vial of 10 doses (20 ml).20 ml Type-I colourless glass vials, closed with type I rubber stoppers and aluminium caps.
  • Cardboard box with1 Glass vial of 50 doses (100 ml). 100 ml Type-I colourless glass vials, closed with type I rubber stoppers and aluminium caps.
  • Cardboard box with 1 PET vial of 25 doses (50 ml). , 50 ml PET plastic vials, closed with type I rubber stoppers and aluminium caps
  • Cardboard box with 1 PET vial of 10 doses (20 ml).20 ml PET plastic vials, closed with type I rubber stoppers and aluminium caps.

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Laboratorios Hipra S.A.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Laboratorios Hipra S.A.
Responsible authority:
  • Finnish Medicines Agency
Authorisation number:
  • 25275
Date of authorisation status change:
Reference member state:
  • Spain
Procedure number:
  • ES/V/0461/001
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."